| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
24,270,000 |
| Market
Cap: |
516.22(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$20.03 - $40.81 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fulgent Genetics is a holding company. Through its subsidiaries, Co. is a technology company providing COVID-19 testing services, molecular diagnostic testing services and genetic testing designed to provide physicians and patients with clinically actionable diagnostic information to improve the quality of patient care. Co. has developed a proprietary technology platform allowing Co. to provide a test menu. Combining next generation sequencing with its technology platform, Co. performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels that can be tailored to meet customer needs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
29,577 |
54,115 |
78,957 |
| Total Sell Value |
$0 |
$791,434 |
$1,639,451 |
$2,902,369 |
| Total People Sold |
0 |
3 |
3 |
4 |
| Total Sell Transactions |
0 |
6 |
19 |
36 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hsieh Ming |
Chief Executive Officer |
• • • |
2023-08-01 |
4 |
D |
$38.83 |
$185,724 |
D/D |
(4,783) |
643,772 |
|
- |
|
| Xie Jian |
President and COO |
• – – |
2023-08-01 |
4 |
D |
$38.83 |
$30,093 |
D/D |
(775) |
425,019 |
|
- |
|
| Gao Hanlin |
Chief Scientific Officer |
• – – |
2023-07-30 |
4 |
D |
$38.63 |
$2,936 |
D/D |
(76) |
914,315 |
|
- |
|
| Gao Hanlin |
Chief Scientific Officer |
• – – |
2023-06-02 |
4 |
S |
$40.30 |
$40,296 |
D/D |
(1,000) |
914,391 |
|
37% |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2023-06-02 |
4 |
S |
$40.30 |
$56,535 |
D/D |
(1,403) |
228,890 |
|
37% |
|
| Xie Jian |
President and COO |
• – – |
2023-06-02 |
4 |
S |
$40.30 |
$57,744 |
D/D |
(1,433) |
425,794 |
|
37% |
|
| Marsh Linda |
Director |
– • – |
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
5,059 |
10,659 |
|
- |
|
| Nohaile Michael |
Director |
– • – |
2023-05-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,529 |
6,529 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2023-05-17 |
4 |
S |
$35.46 |
$44,895 |
D/D |
(1,266) |
230,293 |
|
23% |
|
| Gao Hanlin |
Chief Scientific Officer |
• – – |
2023-05-17 |
4 |
S |
$35.46 |
$12,234 |
D/D |
(345) |
915,391 |
|
23% |
|
| Xie Jian |
President and COO |
• – – |
2023-05-17 |
4 |
S |
$35.46 |
$46,810 |
D/D |
(1,320) |
427,227 |
|
23% |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2023-05-03 |
4 |
D |
$29.33 |
$25,370 |
D/D |
(865) |
231,559 |
|
- |
|
| Xie Jian |
President and COO |
• – – |
2023-05-03 |
4 |
D |
$29.33 |
$181,787 |
D/D |
(6,198) |
428,547 |
|
- |
|
| Xie Jian |
President and COO |
• – – |
2023-05-01 |
4 |
D |
$29.90 |
$23,173 |
D/D |
(775) |
434,745 |
|
- |
|
| Gao Hanlin |
Chief Scientific Officer |
• – – |
2023-04-30 |
4 |
D |
$29.57 |
$2,247 |
D/D |
(76) |
915,736 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2023-03-01 |
4 |
D |
$31.85 |
$134,980 |
D/D |
(4,238) |
232,424 |
|
- |
|
| Xie Jian |
President and COO |
• – – |
2023-03-01 |
4 |
D |
$31.85 |
$128,833 |
D/D |
(4,045) |
435,520 |
|
- |
|
| Gao Hanlin |
Chief Scientific Officer |
• – – |
2023-03-01 |
4 |
D |
$31.85 |
$121,157 |
D/D |
(3,804) |
915,812 |
|
- |
|
| Xie Jian |
President and COO |
• – – |
2023-02-27 |
4 |
D |
$32.67 |
$14,146 |
D/D |
(433) |
439,565 |
|
- |
|
| Gao Hanlin |
Chief Scientific Officer |
• – – |
2023-02-23 |
4 |
D |
$31.65 |
$25,130 |
D/D |
(794) |
919,616 |
|
- |
|
| Gao Hanlin |
Chief Scientific Officer |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
14,298 |
920,410 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2023-02-23 |
4 |
D |
$31.65 |
$23,453 |
D/D |
(741) |
236,662 |
|
- |
|
| Kim Paul |
CFO and Treasurer |
• – – |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
16,360 |
237,403 |
|
- |
|
| Hsieh Ming |
Chief Executive Officer |
• • • |
2023-02-23 |
4 |
D |
$31.65 |
$83,081 |
D/D |
(2,625) |
648,555 |
|
- |
|
| Hsieh Ming |
Chief Executive Officer |
• • • |
2023-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
55,009 |
651,180 |
|
- |
|
281 Records found
|
|
Page 3 of 12 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.05 (0.23%) 
